This document is page 69 of a 2017 report by Ackrell Capital, LLC, titled 'Chapter IV U.S. Legal Landscape.' It provides a legal overview of the Controlled Substances Act (CSA), detailing the criteria for Schedule I-V drugs and specifically focusing on the classification and definition of marijuana as a Schedule I substance. The document bears a 'HOUSE_OVERSIGHT_024705' Bates stamp, suggesting it was included in evidence for a House Oversight Committee investigation, likely related to financial reviews.
| Name | Type | Context |
|---|---|---|
| Ackrell Capital, LLC |
Header and footer indicate this is a report produced by this firm.
|
|
| DEA |
Drug Enforcement Administration; mentioned regarding enforcement of the CSA.
|
|
| U.S. Congress |
Mentioned as having the power to legislate substance scheduling.
|
|
| U.S. Department of Health and Human Services |
DHHS; involved in recommendations for scheduling substances.
|
|
| U.S. Food and Drug Administration |
Agency of the DHHS charged with safety-related determinations.
|
|
| FINRA |
Financial Industry Regulatory Authority (Footer).
|
|
| SIPC |
Securities Investor Protection Corporation (Footer).
|
| Location | Context |
|---|---|
|
Jurisdiction for the CSA and medical use standards.
|
"Current Schedule I substances include marijuana, THC, heroin, ecstasy, LSD and peyote."Source
"Marijuana has been a Schedule I controlled substance since enactment of the CSA in 1970."Source
"The CSA does not restrict such non-marijuana products"Source
Complete text extracted from the document (3,192 characters)
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document